Suppr超能文献

[晚期非小细胞肺癌的预后因素]

[Prognostic factors of advanced stage non-small-cell lung cancer].

作者信息

Kwas H, Guermazi E, Khattab A, Hrizi C, Zendah I, Ghédira H

机构信息

Service de pneumologie I, hôpital Abderrahmane-Mami-de-l'Ariana, faculté de médecine de Tunis, université El-Manar de Tunis, 2080 Tunis, Tunisie.

Service de pneumologie I, hôpital Abderrahmane-Mami-de-l'Ariana, faculté de médecine de Tunis, université El-Manar de Tunis, 2080 Tunis, Tunisie.

出版信息

Rev Pneumol Clin. 2017 Sep;73(4):180-187. doi: 10.1016/j.pneumo.2017.05.002. Epub 2017 Jul 26.

Abstract

INTRODUCTION

Primary lung cancer is the leading cause of cancer death in men in the world. Although the introduction of new drugs, new therapeutic strategies and despite therapeutic advances, the prognosis is relatively improved during the last years.

AIM

To evaluate the prognosis of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) and to identify prognostic factors at these stages.

METHODS

A retrospective study, including 140 cases of locally advanced or metastatic NSCLC diagnosed in our department between 2003 and 2013.

RESULTS

The average age was 61±10 years (35 to 90 years). Sex ratio was 18. The delays management were 80±25 days for presentation, 45±20 days for the diagnostic, while the treatment delay was 8±2.33 days. The cancer was at stage IIIA in 14%, IIIB in 27% and IV in 59%. Six months and one-year survival was between 50 and 74% and between 9 and 25%, respectively. Better survival was observed in patients with NSCLC on stage III, having better performance status, having comorbid conditions, with prolonged delays management, a short therapeutic delay and patients who received specific antitumor treatment.

CONCLUSION

The prognostic factors in locally advanced and metastatic NSCLC in our patients were: stage of cancer, performance status, comorbid conditions, delay of management and specific antitumoral treatment. These factors should be considered in the management of patients with advanced NSCLC.

摘要

引言

原发性肺癌是全球男性癌症死亡的主要原因。尽管引入了新药、新治疗策略,且治疗取得了进展,但在过去几年中预后仍相对有所改善。

目的

评估局部晚期或转移性非小细胞肺癌(NSCLC)患者的预后,并确定这些阶段的预后因素。

方法

一项回顾性研究,纳入2003年至2013年间在我科诊断的140例局部晚期或转移性NSCLC患者。

结果

平均年龄为61±10岁(35至90岁)。性别比为18。就诊延迟时间为80±25天,诊断延迟时间为45±20天,而治疗延迟时间为8±2.33天。癌症处于ⅢA期的占14%,ⅢB期的占27%,Ⅳ期的占59%。六个月和一年生存率分别在50%至74%和9%至25%之间。在Ⅲ期NSCLC患者中观察到更好的生存率,这些患者具有更好的体能状态、合并症、就诊延迟时间延长、治疗延迟时间短以及接受了特定抗肿瘤治疗。

结论

我们患者中局部晚期和转移性NSCLC的预后因素为:癌症分期、体能状态、合并症、就诊延迟和特定抗肿瘤治疗。在晚期NSCLC患者的管理中应考虑这些因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验